Xie Yanru, Huang Jianhui, Wu Minhua, Zhou Yuefen
Department of Oncology, Lishui Central Hospital, Zhejiang Lishui, PR China.
J Cancer Res Ther. 2018;14(4):892-895. doi: 10.4103/jcrt.JCRT_461_17.
The objective of this study is to evaluate the association between expression of CD133 protein and the clinicopathological features of patients with osteosarcoma.
This study retrospectively analyzed 28 cases of osteosarcoma in our hospital from 2007 to 2016, as well as 21 cases of osteochondroma in the same period as control group. The expression of CD133 protein in paraffin specimens of two groups of patients was detected with immunohistochemistry SP assay.
CD133-positive staining was observed in the cytoplasm or cell membrane. The positive rate of CD133 protein expression in osteosarcoma tissue was significantly higher than that of in osteochondroma (60.7% vs. 19.0%), with statistically significant difference (P < 0.01). The patients of osteosarcoma were followed up for 11-94 months, and the median survival time was 47 months. During follow-up period, there were 16 cases of lung, spine, or retroperitoneal metastasis. At the end of the follow-up, 15 cases were dead and 13 cases were still alive. Distant metastasis and Enneking staging were significantly correlated with CD133-positive expression in osteosarcoma patients (P < 0.05), and the proportion of CD133-positive expression was high in both distant metastasis and Enneking staging. The median disease-free survival time was 21 and 32 months for CD133-positive and CD133-negative expression patients with osteosarcoma, respectively, with statistically significant difference (P < 0.05). However, the median survival time of the CD133-positive and CD133-negative expression groups was 46 and 49 months, without statistically significant difference (P > 0.05).
The expression of CD133 protein in patients with osteosarcoma was significantly high and related to the distant metastasis, which may be a potential prediction biomarker for poor prognosis of osteosarcoma patients.
本研究旨在评估CD133蛋白表达与骨肉瘤患者临床病理特征之间的关联。
本研究回顾性分析了我院2007年至2016年的28例骨肉瘤病例，以及同期21例骨软骨瘤病例作为对照组。采用免疫组织化学SP法检测两组患者石蜡标本中CD133蛋白的表达。
CD133阳性染色见于细胞质或细胞膜。骨肉瘤组织中CD133蛋白表达阳性率显著高于骨软骨瘤（60.7%对19.0%），差异有统计学意义（P<0.01）。对骨肉瘤患者进行了11至94个月的随访，中位生存时间为47个月。随访期间，有16例发生肺、脊柱或腹膜后转移。随访结束时，15例死亡，13例仍存活。远处转移和Enneking分期与骨肉瘤患者CD133阳性表达显著相关（P<0.05），远处转移和Enneking分期中CD133阳性表达比例均较高。骨肉瘤CD133阳性和阴性表达患者的无病生存期中位数分别为21个月和32个月，差异有统计学意义（P<0.05）。然而，CD133阳性和阴性表达组的中位生存时间分别为46个月和49个月，差异无统计学意义（P>0.05）。
骨肉瘤患者CD133蛋白表达显著升高，且与远处转移相关，可能是骨肉瘤患者预后不良的潜在预测生物标志物。
